LumiQuick Diagnostics

Executive Summary

LumiQuick Diagnostics, founded in 2020 and headquartered in San Diego with operations in Santa Clara, CA, is a private diagnostics company focused on developing and commercializing rapid immunochromatographic assays (lateral flow tests) and ELISA kits. The company targets a wide range of applications including infectious diseases, drugs of abuse, cardiac markers, veterinary diagnostics, and biothreat detection. By leveraging its core platform technology, LumiQuick aims to deliver simple, quick, and accurate diagnostic tools that can be deployed in point-of-care settings, clinical laboratories, and field environments. The company's mission is to partner with healthcare providers to improve patient outcomes through accessible diagnostics. As a private entity, LumiQuick has not disclosed funding or valuation details, but its presence in the competitive diagnostics space suggests ongoing product development and potential regulatory submissions. The company is well-positioned to capitalize on the growing demand for rapid testing, particularly in infectious disease and point-of-care markets.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for a new rapid infectious disease test50% success
• Q1 2027Strategic partnership or distribution agreement for international markets40% success
• Q3 2026Launch of a multiplex lateral flow assay for respiratory pathogens30% success